Literature DB >> 10854165

Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2.

A Mörner1, A Achour, M Norin, R Thorstensson, E Björling.   

Abstract

We have previously identified two distinct antigenic sites in the third variable region (V3) of human immunodeficiency virus type 2 (HIV-2) corresponding to the principal neutralizing determinant (PND) of HIV-1, the conserved Phe-His-Ser-Gln and Trp-Cys-Arg motifs (positions 315-318 and 329-331), which possibly interact to form a discontinuous antigenic site. The aim of this study was to further identify and characterize the immunogenic sites in the V3-loop of HIV-2 that are important in the binding of neutralizing antibodies and to study in detail the importance of different configurations of peptides corresponding to this region. Peptides representing modifications of the V3-region of HIV-2(SBL6669-ISY) were used for immunization of guinea pigs. With one exception, both the Phe-His-Ser-Gln and the Trp-Cys-Arg motifs were required in the peptide sequences to obtain neutralizing hyperimmune guinea pig sera, and the highest titers were obtained after immunization with 20-27 amino acids (aa) long peptides. Neither substitutions nor deletions of residues between the two motifs, nor the addition of peptide sequences representing a T-helper epitope improved the induction of neutralizing antibodies. Computer simulation modeling revealed that the Phe-315, His-316, Trp-329 and Cys-330 are likely to participate in the formation of a discontinuous epitope. Taken together, these data support the hypothesis that the well conserved motifs FHSQ (positions 315-318) and WCR (positions 329-331) of the HIV-2(SBL6669) V3 region are important targets for neutralizing antibodies, and this may have implications for the design of a future HIV-2 vaccine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10854165     DOI: 10.1016/s0168-1702(98)00133-6

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  5 in total

1.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8.

Authors:  Hannes Uchtenhagen; Samer Sourial; Rosmarie Friemann; Mariethe Ehnlund; Anna-Lena Spetz; Robert A Harris; Chaithanya Madhurantakam; Adnane Achour
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

3.  Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Authors:  Helena Barroso; Pedro Borrego; Inês Bártolo; José Maria Marcelino; Carlos Família; Alexandre Quintas; Nuno Taveira
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

4.  Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125.

Authors:  Hannes Uchtenhagen; Rosmarie Friemann; Grzegorz Raszewski; Anna-Lena Spetz; Lennart Nilsson; Adnane Achour
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

5.  HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development.

Authors:  Batul Diwan; Rupali Saxena; Archana Tiwari
Journal:  Springerplus       Date:  2013-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.